In Brief: Baxter's HemAssist
Baxter's HemAssist: Hemoglobin therapeutic cleared by FDA for Phase III trials to investigate product's effect on survival rates in patients with severe trauma, company announces Nov. 21. Trial will begin enrolling patients by early 1997 and will compare outcomes of accident and trauma victims resuscitated with current standard of care compared to those resuscitated with HemAssist in addition to current standard of care. HemAssist is also enrolling patients in a Phase III trial of HemAssist for use with surgery...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth